Breaking News

Today
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Conference/Events
Vincerx Pharma to hold a Key Opinion Leader conference call » 10:07
04/16/21
04/16
10:07
04/16/21
10:07
VINC

Vincerx Pharma

$18.40 /

+0.125 (+0.68%)

Dr. Druker of Knight…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
VINC Vincerx Pharma
$18.40 /

+0.125 (+0.68%)

VINC Vincerx Pharma
$18.40 /

+0.125 (+0.68%)

01/06/21 Chardan
Vincera Pharma initiated with a Buy at Chardan
VINC Vincerx Pharma
$18.40 /

+0.125 (+0.68%)

Sunday
Hot Stocks
Vincera Pharma presents preclinical data on VIP236 at AACR Meeting » 17:10
04/11/21
04/11
17:10
04/11/21
17:10
VINC

Vincera Pharma

$19.05 /

+0.03 (+0.16%)

Vincerx Pharma presented…

Vincerx Pharma presented preclinical data characterizing VIP236, a novel small molecule drug conjugate at the American Association for Cancer Research Annual Meeting 2021. The SMDC is comprised of an alphavbeta3 integrin antagonist linked to a cytotoxic camptothecin derivative, designed to selectively release its payload via neutrophil elastase in the tumor microenvironment. VIP236 is a novel SMDC targeted by an alphavbeta3 integrin antagonist with a neutrophil elastase cleavable linker linked to a modified CPT payload derived from SN38, a well-known cytotoxic drug and active metabolite of irinotecan. Efficient anti-tumor targeting and greater cytotoxicity is achieved by multiple mechanisms associated with aggressive tumor cells and its microenvironment. VIP236 targets alphavbeta3 integrin which is overexpressed by invasive cancer and stromal cells in the TME such as endothelial cells undergoing neovascularization. Efficient tumor homing with the alphavbeta3 integrin antagonist is demonstrated by the imaging studies. Neutrophil elastase is overexpressed in the invasive TME associated with advanced cancers. The abundance of NE in the TME promotes linker cleavage, release of the active modified CPT payload and enhances VIP236 cytotoxicity. Drug resistant cancer cells often have greater drug efflux capabilities. The CPT payload is modified to improve cellular permeability and lower cell efflux properties resulting in better cytotoxicity in cancer cells overexpressing drug efflux pumps when compared to SN38. The combination of these properties results in a 10.8-fold higher tumor-to-plasma ratio of the targeted and modified CPT payload compared to administration of the payload alone. In vivo, VIP236 demonstrates higher antitumor efficacy in comparison to reference chemotherapy drugs across multiple mouse xenograft models. Complete tumor responses were observed in 100% of mice across all dose levels in the MX-1 triple negative breast cancer model. Partial responses were observed in 100% of mice in both the NCI-H69 small cell lung cancer and SW480 colorectal cancer mouse models at a VIP236 dose of 40mg/kg. Across mouse models, VIP236 showed good tolerability as evidenced by less than 5% mean body weight loss.

ShowHide Related Items >><<
VINC Vincera Pharma
$19.05 /

+0.03 (+0.16%)

VINC Vincera Pharma
$19.05 /

+0.03 (+0.16%)

01/06/21 Chardan
Vincera Pharma initiated with a Buy at Chardan
VINC Vincera Pharma
$19.05 /

+0.03 (+0.16%)

Over a week ago
Hot Stocks
Vincera Pharma to host KOL webinar on bioconjugation, CDK9 inhibitors » 08:18
04/07/21
04/07
08:18
04/07/21
08:18
VINC

Vincera Pharma

$18.91 /

-0.34 (-1.77%)

Vincerx Pharma announced…

Vincerx Pharma announced that it will be hosting a key opinion leader meeting on bioconjugation and CDK9 inhibitors for the treatment of hematologic and solid tumors on Friday, April 16, 2021 at 12:00 PM ET. The event will feature presentations by KOLs Brian Druker, M.D., Knight Cancer Institute, and Anthony W. Tolcher, M.D., NEXT Oncology. Dr. Tolcher will discuss tackling normal tissue toxicity from antibody-drug conjugates and Dr. Druker will discuss CDK9 in hematologic malignancies. Drs. Druker and Tolcher will be available to answer questions following the formal presentations. Vincerx's management team will discuss its poster titled, "A novel small molecule drug conjugate -alphavbeta3 integrin antagonist linked to a cytotoxic camptothecin derivative- for the treatment of multiple cancer types," which will be presented at the upcoming American Association for Cancer Research Annual Meeting, as well as the Company's bioconjugation platform. Vincerx's preclinical bioconjugation platform seeks to address the current limitations of small-molecule and antibody-drug conjugates in oncology and consists of VIP236, a small molecule drug conjugate targeting advanced and metastatic cancer, as well as VIP943 and VIP924, two ADCs targeting hematologic tumors.

ShowHide Related Items >><<
VINC Vincera Pharma
$18.91 /

-0.34 (-1.77%)

VINC Vincera Pharma
$18.91 /

-0.34 (-1.77%)

01/06/21 Chardan
Vincera Pharma initiated with a Buy at Chardan
VINC Vincera Pharma
$18.91 /

-0.34 (-1.77%)

Hot Stocks
Vincera Pharma announces formation of Scientific Advisory Board » 08:08
04/01/21
04/01
08:08
04/01/21
08:08
VINC

Vincera Pharma

$19.36 /

+0.06 (+0.31%)

Vincerx Pharma announced…

Vincerx Pharma announced the formation of its Scientific Advisory Board composed of world leading academics and industry leaders in cancer research and therapeutics. John Byrd, M.D., will serve as Chairman of the SAB. Vincerx's SAB is comprised of: John Byrd. Byrd is an internationally known researcher and clinical specialist in leukemia and other hematologic malignancies at Ohio State's Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute, where he serves as Senior Advisor for Cancer Experimental Therapeutics. Howard A. "Skip" Burris III, M.D., FASCO, FACP. Burris serves as President and Chief Medical Officer of Sarah Cannon, as well as the Executive Director, drug development for Sarah Cannon Research Institute. Gerard Evan, Ph.D. Dr. Evan is the Sir William Dunn Professor and Head of Biochemistry at the University of Cambridge. Ian W. Flinn, M.D., Ph.D. Dr. Flinn is an internationally recognized clinical investigator whose research focuses on the development of new therapies for patients with lymphoma and chronic lymphocytic leukemia. Andre Goy, M.D., M.S. Dr. Goy is an internationally renowned clinician and researcher of all types of lymphoma, including Hodgkin's disease, non-Hodgkin's lymphoma including aggressive lymphoma and mantle cell lymphoma, and HIV-associated lymphoma. As Physician in Chief for Hackensack Meridian Health Oncology Services and Chairman of John Theurer Cancer Center at Hackensack University Medical Center as well as Founding Chair of Oncology at the Hackensack Meridian Health School of Medicine, he leads New Jersey's largest program for research, treatment and management of lymphoma. Rosa Lapalombella, Ph.D. Dr. Lapalombella, Assistant Professor at The Ohio State University, has a strong history of translational medical research. Anthony W. Tolcher, M.D., FRCPS, FACP. Dr. Tolcher is CEO and Founder of NEXT Oncology.

ShowHide Related Items >><<
VINC Vincera Pharma
$19.36 /

+0.06 (+0.31%)

VINC Vincera Pharma
$19.36 /

+0.06 (+0.31%)

01/06/21 Chardan
Vincera Pharma initiated with a Buy at Chardan
VINC Vincera Pharma
$19.36 /

+0.06 (+0.31%)

Earnings
Vincera Pharma reports 2020 EPS ($2.04), two est. ($1.82) » 08:05
03/23/21
03/23
08:05
03/23/21
08:05
VINC

Vincera Pharma

$23.30 /

-1.44 (-5.82%)

"Over the past…

"Over the past months, Vincerx has completed transformative milestones; licensing a compelling oncology pipeline from Bayer, launching as a public company, and strengthening our already proven leadership team," said Ahmed Hamdy M.D., CEO of Vincerx. "These accomplishments, in combination with our strong balance sheet, leave us well positioned as we prepare to launch Phase 1b studies of VIP152, our highly selective and potent CDK9 inhibitor, in Myc-driven hematologic malignancies and solid tumors, as well as relapsed/refractory chronic lymphocytic leukemia. With robust preclinical on-mechanism activity, and compelling early signals of Phase 1 clinical activity in challenging patient populations, including those with double-hit DLBCL, we are confident that VIP152 represents a compelling and differentiated opportunity. In addition to this clinical progress, we have in parallel continued to develop our preclinical bioconjugation platform, consisting of our next-generation antibody-drug conjugates which have the potential to overcome limitations of currently approved ADCs and our innovative small molecule drug conjugate, which will have data presented at AACR. We are excited to embark on this new phase of development and look forward to continued execution in 2021 across our strategic clinical program with VIP152, a potential best-in-class asset with multiple Accelerated Approval opportunities."

ShowHide Related Items >><<
VINC Vincera Pharma
$23.30 /

-1.44 (-5.82%)

VINC Vincera Pharma
$23.30 /

-1.44 (-5.82%)

01/06/21 Chardan
Vincera Pharma initiated with a Buy at Chardan
VINC Vincera Pharma
$23.30 /

-1.44 (-5.82%)

Over a month ago
Conference/Events
Vincera Pharma to host business news update conference call » 11:25
03/05/21
03/05
11:25
03/05/21
11:25
VINC

Vincera Pharma

$18.00 /

-1.17 (-6.10%)

Management, along with…

Management, along with Key Opinion Leaders Ian Flinn, MD, PhD, John Byrd, MD and Howard Burns, III MD, discuss the CDK9 inhibitor landscape in hematologic and solid tumors, as well as Vincerx's lead product, VIP152 a CDK9 inhibitor optimized for intermittent intravenous treatment on a conference call to be held on March 5 at 12 pm. Webcast Link

ShowHide Related Items >><<
VINC Vincera Pharma
$18.00 /

-1.17 (-6.10%)

VINC Vincera Pharma
$18.00 /

-1.17 (-6.10%)

01/06/21 Chardan
Vincera Pharma initiated with a Buy at Chardan
VINC Vincera Pharma
$18.00 /

-1.17 (-6.10%)

Conference/Events
Vincera Pharma to host business news update conference call » 07:58
03/05/21
03/05
07:58
03/05/21
07:58
VINC

Vincera Pharma

$19.16 /

-1.26 (-6.17%)

Management, along with…

Management, along with Key Opinion Leaders Ian Flinn, MD, PhD, John Byrd, MD and Howard Burns, III MD, discuss the CDK9 inhibitor landscape in hematologic and solid tumors, as well as Vincerx's lead product, VIP152 a CDK9 inhibitor optimized for intermittent intravenous treatment on a conference call to be held on March 5 at 12 pm. Webcast Link

ShowHide Related Items >><<
VINC Vincera Pharma
$19.16 /

-1.26 (-6.17%)

VINC Vincera Pharma
$19.16 /

-1.26 (-6.17%)

01/06/21 Chardan
Vincera Pharma initiated with a Buy at Chardan
VINC Vincera Pharma
$19.16 /

-1.26 (-6.17%)

Hot Stocks
Vincera Pharma appoints Hermes Garban as CMO, Hans-Georg Lerchen as CSO » 08:06
03/02/21
03/02
08:06
03/02/21
08:06
VINC

Vincera Pharma

$19.24 /

+0.23 (+1.21%)

Vincerx Pharma announced…

Vincerx Pharma announced the addition of three new executives to the company's management team. Hermes Garban, M.D., Ph.D. has been appointed as Chief Medical Officer, Hans-Georg Lerchen, Ph.D. has been appointed as Chief Scientific Officer, and Tom Thomas, has been appointed as General Counsel and Chief Legal Officer of Vincerx. Hermes Garban, M.D., Ph.D. is the Chief Medical Officer of Vincerx Pharma, Inc. Before joining Vincerx, Dr. Garban served as Head, Therapeutics Discovery and Development at ImmunityBio, Inc., a registration stage immuno-oncology and infectious disease company responsible for conducting Phase 1 through Phase 3 clinical trials focusing on solid tumors and immunotherapies development, from March 2019 to February 2021. Hans-Georg Lerchen, Ph.D. is the Chief Scientific Officer of Vincerx. Before joining Vincerx, Dr. Lerchen was a Distinguished Fellow in the Bayer Science Fellow Network of the Pharmaceuticals R&D organization of Bayer AG. Tom Thomas will be joining as General Counsel and Chief Legal Officer of Vincerx on March 15. Mr. Thomas is a partner at Pillsbury Winthrop Shaw Pittman LLP, a leading international law firm with offices in major metropolitan centers around the world.

ShowHide Related Items >><<
VINC Vincera Pharma
$19.24 /

+0.23 (+1.21%)

VINC Vincera Pharma
$19.24 /

+0.23 (+1.21%)

01/06/21 Chardan
Vincera Pharma initiated with a Buy at Chardan
VINC Vincera Pharma
$19.24 /

+0.23 (+1.21%)

Conference/Events
SVB Leerink to hold a virtual conference » 04:55
02/26/21
02/26
04:55
02/26/21
04:55
ACRS

Aclaris Therapeutics

$21.24 /

+0.52 (+2.51%)

, BBIO

BridgeBio

$65.26 /

-2.3001 (-3.40%)

, HLIO

Helios Technologies

$65.84 /

-1.11 (-1.66%)

, MTCR

Metracrine

$8.57 /

-0.24 (-2.72%)

, SIEN

Sientra

$7.70 /

-0.355 (-4.41%)

, TRVI

Trevi Therapeutics

$2.82 /

-0.07 (-2.42%)

, VCYT

Veracyte

$58.71 /

-3.635 (-5.83%)

, VINC

Vincera Pharma

$19.19 /

-0.92 (-4.57%)

, CTSO

CytoSorbents

$9.70 /

-0.44 (-4.34%)

, CTLT

Catalent

$112.25 /

-2.87 (-2.49%)

, IMRA

Imara

$12.49 /

-0.45 (-3.48%)

, ITOS

iTeos Therapeutics

$41.77 /

+0.77 (+1.88%)

, LLY

Eli Lilly

$203.91 /

-0.735 (-0.36%)

, AUPH

Aurinia Pharmaceuticals

$14.59 /

+0.015 (+0.10%)

, AVXL

Anavex

$13.01 /

+0.65 (+5.26%)

, DRIO

DarioHealth

$27.17 /

-2.22 (-7.55%)

, ENTA

Enanta

$50.58 /

-1.1548 (-2.23%)

, EQ

Equillium

$7.65 /

-0.22 (-2.80%)

, EXEL

Exelixis

$21.96 /

-0.73 (-3.22%)

, SDGR

Schrodinger

$104.43 /

-6.46 (-5.83%)

10th Annual Global…

10th Annual Global Healthcare Virtual Conference will be held on February 22-26.

ShowHide Related Items >><<
VINC Vincera Pharma
$19.19 /

-0.92 (-4.57%)

VCYT Veracyte
$58.71 /

-3.635 (-5.83%)

TRVI Trevi Therapeutics
$2.82 /

-0.07 (-2.42%)

SIEN Sientra
$7.70 /

-0.355 (-4.41%)

SDGR Schrodinger
$104.43 /

-6.46 (-5.83%)

MTCR Metracrine
$8.57 /

-0.24 (-2.72%)

LLY Eli Lilly
$203.91 /

-0.735 (-0.36%)

ITOS iTeos Therapeutics
$41.77 /

+0.77 (+1.88%)

IMRA Imara
$12.49 /

-0.45 (-3.48%)

HLIO Helios Technologies
$65.84 /

-1.11 (-1.66%)

EXEL Exelixis
$21.96 /

-0.73 (-3.22%)

EQ Equillium
$7.65 /

-0.22 (-2.80%)

ENTA Enanta
$50.58 /

-1.1548 (-2.23%)

DRIO DarioHealth
$27.17 /

-2.22 (-7.55%)

CTSO CytoSorbents
$9.70 /

-0.44 (-4.34%)

CTLT Catalent
$112.25 /

-2.87 (-2.49%)

BBIO BridgeBio
$65.26 /

-2.3001 (-3.40%)

AVXL Anavex
$13.01 /

+0.65 (+5.26%)

AUPH Aurinia Pharmaceuticals
$14.59 /

+0.015 (+0.10%)

ACRS Aclaris Therapeutics
$21.24 /

+0.52 (+2.51%)

ACRS Aclaris Therapeutics
$21.24 /

+0.52 (+2.51%)

02/02/21 Cantor Fitzgerald
Aclaris Therapeutics price target raised to $30 from $15 at Cantor Fitzgerald
01/19/21 William Blair
Aclaris has potential in range of 'blockbuster indications,' says William Blair
BBIO BridgeBio
$65.26 /

-2.3001 (-3.40%)

02/22/21 JPMorgan
BridgeBio reinstated with an Overweight at JPMorgan
02/09/21
Fly Intel: Top five analyst initiations
02/09/21 Goldman Sachs
BridgeBio reinstated with a Buy at Goldman Sachs
01/11/21 H.C. Wainwright
BridgeBio price target raised to $87 from $64 at H.C. Wainwright
HLIO Helios Technologies
$65.84 /

-1.11 (-1.66%)

10/12/20 Baird
Helios Technologies upgraded to Outperform from Neutral at Baird
05/29/20 Morgan Stanley
Morgan Stanley upgrades Helios to Equal Weight following underperformance
05/29/20 Morgan Stanley
Helios Technologies upgraded to Equal Weight from Underweight at Morgan Stanley
03/27/20 Truist
Helios Technologies price target lowered to $36 from $45 at SunTrust
MTCR Metracrine
$8.57 /

-0.24 (-2.72%)

10/12/20 Canaccord
Metracrine initiated with a Buy at Canaccord
10/12/20 Jefferies
Metracrine initiated with a Buy at Jefferies
10/12/20 RBC Capital
Metracrine initiated with an Outperform at RBC Capital
SIEN Sientra
$7.70 /

-0.355 (-4.41%)

02/05/21 Canaccord
Sientra price target raised to $8 from $6 at Canaccord
10/08/20 Stifel
Stifel sees upside potential for Sientra after survey of aesthetics doctors
06/11/20 Maxim
Sientra price target raised to $8 from $5 at Maxim
03/12/20 Craig-Hallum
Sientra price target lowered to $9 from $14 at Craig-Hallum
TRVI Trevi Therapeutics
$2.82 /

-0.07 (-2.42%)

07/13/20 Stifel
Trevi Therapeutics price target lowered to $10 from $14 at Stifel
VCYT Veracyte
$58.71 /

-3.635 (-5.83%)

02/18/21 Needham
Veracyte assumed with a Buy at Needham
02/08/21 SVB Leerink
Veracyte price target raised to $83 from $40 at SVB Leerink
01/27/21 Truist
Veracyte initiated with a Buy at Truist
12/17/20 Lake Street
Veracyte price target raised to $60 from $40 at Lake Street
VINC Vincera Pharma
$19.19 /

-0.92 (-4.57%)

01/06/21 Chardan
Vincera Pharma initiated with a Buy at Chardan
CTSO CytoSorbents
$9.70 /

-0.44 (-4.34%)

01/04/21 B. Riley
CytoSorbents price target raised to $17 from $16 at B. Riley Securities
09/01/20 SVB Leerink
CytoSorbents initiated with an Outperform at SVB Leerink
08/25/20 B. Riley
CytoSorbents 29% pullback from highs a buying opportunity, says B. Riley FBR
06/02/20 B. Riley
CytoSorbents gaining relevance as COVID-19 treatment, says B. Riley FBR
CTLT Catalent
$112.25 /

-2.87 (-2.49%)

02/03/21 UBS
Catalent price target raised to $135 from $115 at UBS
02/03/21 RBC Capital
Catalent price target raised to $137 from $125 at RBC Capital
01/08/21 JPMorgan
Catalent price target raised to $130 from $110 at JPMorgan
01/04/21 Stephens
Brinker, LiveRamp and Vonage among 2021 best ideas at Stephens
IMRA Imara
$12.49 /

-0.45 (-3.48%)

01/06/21 SVB Leerink
Imara selloff a potential buying opportunity, says SVB Leerink
08/17/20
Fly Intel: Top five analyst upgrades
08/17/20 Citi
Imara upgraded to Buy from Neutral at Citi
06/30/20 Citi
Imara downgraded to Neutral from Buy at Citi
ITOS iTeos Therapeutics
$41.77 /

+0.77 (+1.88%)

10/07/20 Baird
iTeos Therapeutics initiated with an Outperform at Baird
09/18/20 Piper Sandler
Piper Sandler lays out next potential takeover targets in oncology
09/01/20 Piper Sandler
iTeos Therapeutics heading for 'catalyst rich stretch', says Piper Sandler
08/18/20 SVB Leerink
SVB Leerink bullish on iTeos Therapeutics, initiates with an Outperform
LLY Eli Lilly
$203.91 /

-0.735 (-0.36%)

02/18/21 H.C. Wainwright
Rigel Pharmaceuticals price target raised to $11 from $8 at H.C. Wainwright
02/18/21 Piper Sandler
Rigel share setup 'distinctly positive' after Lilly deal, says Piper Sandler
02/12/21 Cowen
Eli Lilly price target raised to $235 from $195 at Cowen
02/08/21 SVB Leerink
AbCellera price target raised to $52 from $45 at SVB Leerink
AUPH Aurinia Pharmaceuticals
$14.59 /

+0.015 (+0.10%)

01/26/21 RBC Capital
Aurinia Pharmaceuticals price target raised to $28 from $20 at RBC Capital
01/26/21 Cantor Fitzgerald
Aurinia Pharmaceuticals price target raised to $34 from $27 at Cantor Fitzgerald
01/25/21 Oppenheimer
Aurinia Pharmaceuticals price target raised to $28 from $20 at Oppenheimer
01/25/21 H.C. Wainwright
Aurinia Pharmaceuticals price target raised to $35 from $30 at H.C. Wainwright
AVXL Anavex
$13.01 /

+0.65 (+5.26%)

02/24/21 Cantor Fitzgerald
Anavex price target raised to $25 from $10 at Cantor Fitzgerald
02/23/21 Cantor Fitzgerald
Anavex price target raised to $25 from $10 at Cantor Fitzgerald
12/29/20 Cantor Fitzgerald
Anavex cash position to fund operations into 2022, says Cantor Fitzgerald
12/16/20 H.C. Wainwright
Anavex price target raised to $17 from $14 at H.C. Wainwright
DRIO DarioHealth
$27.17 /

-2.22 (-7.55%)

02/01/21 Alliance Global Partners
DarioHealth downgraded to Neutral from Buy at Alliance Global Partners
08/17/20 Aegis
DarioHealth initiated with a Buy at Aegis
08/13/20 Craig-Hallum
DarioHealth price target raised to $17 from $8 at Craig-Hallum
06/22/20 ThinkEquity
DarioHealth initiated with a Buy at ThinkEquity
ENTA Enanta
$50.58 /

-1.1548 (-2.23%)

02/09/21 RBC Capital
Enanta price target raised to $53 from $47 at RBC Capital
01/29/21 JPMorgan
Enanta upgraded to Neutral with $55 target at JPMorgan
01/29/21 JPMorgan
Enanta upgraded to Neutral from Underweight at JPMorgan
01/08/21 Piper Sandler
Enanta remains 'significantly undervalued,' says Piper Sandler
EQ Equillium
$7.65 /

-0.22 (-2.80%)

11/30/20 H.C. Wainwright
Equillium price target lowered to $12 from $22 at H.C. Wainwright
07/14/20 H.C. Wainwright
Equillium price target raised to $24 from $14 at H.C. Wainwright
07/10/20 Stifel
Equillium transferred with Buy rating, $10 target at Stifel
EXEL Exelixis
$21.96 /

-0.73 (-3.22%)

02/15/21 Piper Sandler
Exelixis price target raised to $36 from $33 at Piper Sandler
01/25/21 Piper Sandler
Piper says Exelixis could have 'blockbuster opportunity' with XL102
01/22/21 Piper Sandler
Exelixis combo approval came a month ahead of PDUFA, says Piper Sandler
01/20/21 William Blair
Exelixis selloff on competitive concerns an 'overreaction,' says William Blair
SDGR Schrodinger
$104.43 /

-6.46 (-5.83%)

01/25/21 BMO Capital
Schrodinger price target raised to $117 from $97 at BMO Capital
11/23/20 BofA
BofA upgrades Schrodinger to Buy after 'major' collaboration announcement
11/23/20 BofA
Schrodinger upgraded to Buy from Neutral at BofA
10/12/20 Jefferies
Schrodinger upgraded to Buy from Hold at Jefferies
VCYT Veracyte
$58.71 /

-3.635 (-5.83%)

SIEN Sientra
$7.70 /

-0.355 (-4.41%)

SDGR Schrodinger
$104.43 /

-6.46 (-5.83%)

MTCR Metracrine
$8.57 /

-0.24 (-2.72%)

LLY Eli Lilly
$203.91 /

-0.735 (-0.36%)

ITOS iTeos Therapeutics
$41.77 /

+0.77 (+1.88%)

IMRA Imara
$12.49 /

-0.45 (-3.48%)

HLIO Helios Technologies
$65.84 /

-1.11 (-1.66%)

EXEL Exelixis
$21.96 /

-0.73 (-3.22%)

EQ Equillium
$7.65 /

-0.22 (-2.80%)

ENTA Enanta
$50.58 /

-1.1548 (-2.23%)

DRIO DarioHealth
$27.17 /

-2.22 (-7.55%)

CTSO CytoSorbents
$9.70 /

-0.44 (-4.34%)

CTLT Catalent
$112.25 /

-2.87 (-2.49%)

BBIO BridgeBio
$65.26 /

-2.3001 (-3.40%)

AVXL Anavex
$13.01 /

+0.65 (+5.26%)

AUPH Aurinia Pharmaceuticals
$14.59 /

+0.015 (+0.10%)

ACRS Aclaris Therapeutics
$21.24 /

+0.52 (+2.51%)

  • 12
    Feb
  • 09
    Feb
  • 05
    Feb
  • 20
    Jan
  • 23
    Nov
  • 16
    Sep
  • 14
    Aug
  • 13
    Aug
  • 05
    Aug
  • 23
    Jul
  • 22
    Jul
  • 24
    Jul
  • 11
    Jun
  • 29
    May
  • 12
    Mar
LLY Eli Lilly
$203.91 /

-0.735 (-0.36%)

BBIO BridgeBio
$65.26 /

-2.3001 (-3.40%)

AUPH Aurinia Pharmaceuticals
$14.59 /

+0.015 (+0.10%)

VINC Vincera Pharma
$19.19 /

-0.92 (-4.57%)

VCYT Veracyte
$58.71 /

-3.635 (-5.83%)

SIEN Sientra
$7.70 /

-0.355 (-4.41%)

SDGR Schrodinger
$104.43 /

-6.46 (-5.83%)

MTCR Metracrine
$8.57 /

-0.24 (-2.72%)

LLY Eli Lilly
$203.91 /

-0.735 (-0.36%)

IMRA Imara
$12.49 /

-0.45 (-3.48%)

EXEL Exelixis
$21.96 /

-0.73 (-3.22%)

EQ Equillium
$7.65 /

-0.22 (-2.80%)

ENTA Enanta
$50.58 /

-1.1548 (-2.23%)

CTLT Catalent
$112.25 /

-2.87 (-2.49%)

BBIO BridgeBio
$65.26 /

-2.3001 (-3.40%)

AVXL Anavex
$13.01 /

+0.65 (+5.26%)

AUPH Aurinia Pharmaceuticals
$14.59 /

+0.015 (+0.10%)

ACRS Aclaris Therapeutics
$21.24 /

+0.52 (+2.51%)

SDGR Schrodinger
$104.43 /

-6.46 (-5.83%)

LLY Eli Lilly
$203.91 /

-0.735 (-0.36%)

AUPH Aurinia Pharmaceuticals
$14.59 /

+0.015 (+0.10%)

Conference/Events
SVB Leerink to hold a virtual conference » 04:55
02/25/21
02/25
04:55
02/25/21
04:55
ACRS

Aclaris Therapeutics

$20.72 /

-0.3 (-1.43%)

, BBIO

BridgeBio

$67.57 /

+1.67 (+2.53%)

, HLIO

Helios Technologies

$66.75 /

+1.46 (+2.24%)

, MTCR

Metracrine

$8.81 /

+0.21 (+2.44%)

, SIEN

Sientra

$8.05 /

-0.04 (-0.49%)

, TRVI

Trevi Therapeutics

$2.88 /

+0.05 (+1.77%)

, VCYT

Veracyte

$62.37 /

+0.88 (+1.43%)

, VINC

Vincera Pharma

$20.21 /

+1.21 (+6.37%)

, CTSO

CytoSorbents

$10.13 /

+0.04 (+0.40%)

, CTLT

Catalent

$115.09 /

+2.215 (+1.96%)

, IMRA

Imara

$12.94 /

+0.62 (+5.03%)

, ITOS

iTeos Therapeutics

$41.00 /

+1.05 (+2.63%)

, LLY

Eli Lilly

$204.64 /

+2.21 (+1.09%)

, AUPH

Aurinia Pharmaceuticals

$14.57 /

+0.21 (+1.46%)

, AVXL

Anavex

$12.38 /

+0.29 (+2.40%)

, DRIO

DarioHealth

$28.90 /

+0.15 (+0.52%)

, ENTA

Enanta

$51.76 /

+0.38 (+0.74%)

, EQ

Equillium

$7.87 /

-0.4 (-4.84%)

, EXEL

Exelixis

$22.69 /

+0.47 (+2.12%)

, SDGR

Schrodinger

$110.89 /

+2.09 (+1.92%)

10th Annual Global…

10th Annual Global Healthcare Virtual Conference will be held on February 22-26.

ShowHide Related Items >><<
VINC Vincera Pharma
$20.21 /

+1.21 (+6.37%)

VCYT Veracyte
$62.37 /

+0.88 (+1.43%)

TRVI Trevi Therapeutics
$2.88 /

+0.05 (+1.77%)

SIEN Sientra
$8.05 /

-0.04 (-0.49%)

SDGR Schrodinger
$110.89 /

+2.09 (+1.92%)

MTCR Metracrine
$8.81 /

+0.21 (+2.44%)

LLY Eli Lilly
$204.64 /

+2.21 (+1.09%)

ITOS iTeos Therapeutics
$41.00 /

+1.05 (+2.63%)

IMRA Imara
$12.94 /

+0.62 (+5.03%)

HLIO Helios Technologies
$66.75 /

+1.46 (+2.24%)

EXEL Exelixis
$22.69 /

+0.47 (+2.12%)

EQ Equillium
$7.87 /

-0.4 (-4.84%)

ENTA Enanta
$51.76 /

+0.38 (+0.74%)

DRIO DarioHealth
$28.90 /

+0.15 (+0.52%)

CTSO CytoSorbents
$10.13 /

+0.04 (+0.40%)

CTLT Catalent
$115.09 /

+2.215 (+1.96%)

BBIO BridgeBio
$67.57 /

+1.67 (+2.53%)

AVXL Anavex
$12.38 /

+0.29 (+2.40%)

AUPH Aurinia Pharmaceuticals
$14.57 /

+0.21 (+1.46%)

ACRS Aclaris Therapeutics
$20.72 /

-0.3 (-1.43%)

ACRS Aclaris Therapeutics
$20.72 /

-0.3 (-1.43%)

02/02/21 Cantor Fitzgerald
Aclaris Therapeutics price target raised to $30 from $15 at Cantor Fitzgerald
01/19/21 William Blair
Aclaris has potential in range of 'blockbuster indications,' says William Blair
BBIO BridgeBio
$67.57 /

+1.67 (+2.53%)

02/22/21 JPMorgan
BridgeBio reinstated with an Overweight at JPMorgan
02/09/21
Fly Intel: Top five analyst initiations
02/09/21 Goldman Sachs
BridgeBio reinstated with a Buy at Goldman Sachs
01/11/21 H.C. Wainwright
BridgeBio price target raised to $87 from $64 at H.C. Wainwright
HLIO Helios Technologies
$66.75 /

+1.46 (+2.24%)

10/12/20 Baird
Helios Technologies upgraded to Outperform from Neutral at Baird
05/29/20 Morgan Stanley
Morgan Stanley upgrades Helios to Equal Weight following underperformance
05/29/20 Morgan Stanley
Helios Technologies upgraded to Equal Weight from Underweight at Morgan Stanley
03/27/20 Truist
Helios Technologies price target lowered to $36 from $45 at SunTrust
MTCR Metracrine
$8.81 /

+0.21 (+2.44%)

10/12/20 Canaccord
Metracrine initiated with a Buy at Canaccord
10/12/20 Jefferies
Metracrine initiated with a Buy at Jefferies
10/12/20 RBC Capital
Metracrine initiated with an Outperform at RBC Capital
SIEN Sientra
$8.05 /

-0.04 (-0.49%)

02/05/21 Canaccord
Sientra price target raised to $8 from $6 at Canaccord
10/08/20 Stifel
Stifel sees upside potential for Sientra after survey of aesthetics doctors
06/11/20 Maxim
Sientra price target raised to $8 from $5 at Maxim
03/12/20 Craig-Hallum
Sientra price target lowered to $9 from $14 at Craig-Hallum
TRVI Trevi Therapeutics
$2.88 /

+0.05 (+1.77%)

07/13/20 Stifel
Trevi Therapeutics price target lowered to $10 from $14 at Stifel
VCYT Veracyte
$62.37 /

+0.88 (+1.43%)

02/18/21 Needham
Veracyte assumed with a Buy at Needham
02/08/21 SVB Leerink
Veracyte price target raised to $83 from $40 at SVB Leerink
01/27/21 Truist
Veracyte initiated with a Buy at Truist
12/17/20 Lake Street
Veracyte price target raised to $60 from $40 at Lake Street
VINC Vincera Pharma
$20.21 /

+1.21 (+6.37%)

01/06/21 Chardan
Vincera Pharma initiated with a Buy at Chardan
CTSO CytoSorbents
$10.13 /

+0.04 (+0.40%)

01/04/21 B. Riley
CytoSorbents price target raised to $17 from $16 at B. Riley Securities
09/01/20 SVB Leerink
CytoSorbents initiated with an Outperform at SVB Leerink
08/25/20 B. Riley
CytoSorbents 29% pullback from highs a buying opportunity, says B. Riley FBR
06/02/20 B. Riley
CytoSorbents gaining relevance as COVID-19 treatment, says B. Riley FBR
CTLT Catalent
$115.09 /

+2.215 (+1.96%)

02/03/21 UBS
Catalent price target raised to $135 from $115 at UBS
02/03/21 RBC Capital
Catalent price target raised to $137 from $125 at RBC Capital
01/08/21 JPMorgan
Catalent price target raised to $130 from $110 at JPMorgan
01/04/21 Stephens
Brinker, LiveRamp and Vonage among 2021 best ideas at Stephens
IMRA Imara
$12.94 /

+0.62 (+5.03%)

01/06/21 SVB Leerink
Imara selloff a potential buying opportunity, says SVB Leerink
08/17/20
Fly Intel: Top five analyst upgrades
08/17/20 Citi
Imara upgraded to Buy from Neutral at Citi
06/30/20 Citi
Imara downgraded to Neutral from Buy at Citi
ITOS iTeos Therapeutics
$41.00 /

+1.05 (+2.63%)

10/07/20 Baird
iTeos Therapeutics initiated with an Outperform at Baird
09/18/20 Piper Sandler
Piper Sandler lays out next potential takeover targets in oncology
09/01/20 Piper Sandler
iTeos Therapeutics heading for 'catalyst rich stretch', says Piper Sandler
08/18/20 SVB Leerink
SVB Leerink bullish on iTeos Therapeutics, initiates with an Outperform
LLY Eli Lilly
$204.64 /

+2.21 (+1.09%)

02/18/21 H.C. Wainwright
Rigel Pharmaceuticals price target raised to $11 from $8 at H.C. Wainwright
02/18/21 Piper Sandler
Rigel share setup 'distinctly positive' after Lilly deal, says Piper Sandler
02/12/21 Cowen
Eli Lilly price target raised to $235 from $195 at Cowen
02/08/21 SVB Leerink
AbCellera price target raised to $52 from $45 at SVB Leerink
AUPH Aurinia Pharmaceuticals
$14.57 /

+0.21 (+1.46%)

01/26/21 RBC Capital
Aurinia Pharmaceuticals price target raised to $28 from $20 at RBC Capital
01/26/21 Cantor Fitzgerald
Aurinia Pharmaceuticals price target raised to $34 from $27 at Cantor Fitzgerald
01/25/21 Oppenheimer
Aurinia Pharmaceuticals price target raised to $28 from $20 at Oppenheimer
01/25/21 H.C. Wainwright
Aurinia Pharmaceuticals price target raised to $35 from $30 at H.C. Wainwright
AVXL Anavex
$12.38 /

+0.29 (+2.40%)

02/24/21 Cantor Fitzgerald
Anavex price target raised to $25 from $10 at Cantor Fitzgerald
02/23/21 Cantor Fitzgerald
Anavex price target raised to $25 from $10 at Cantor Fitzgerald
12/29/20 Cantor Fitzgerald
Anavex cash position to fund operations into 2022, says Cantor Fitzgerald
12/16/20 H.C. Wainwright
Anavex price target raised to $17 from $14 at H.C. Wainwright
DRIO DarioHealth
$28.90 /

+0.15 (+0.52%)

02/01/21 Alliance Global Partners
DarioHealth downgraded to Neutral from Buy at Alliance Global Partners
08/17/20 Aegis
DarioHealth initiated with a Buy at Aegis
08/13/20 Craig-Hallum
DarioHealth price target raised to $17 from $8 at Craig-Hallum
06/22/20 ThinkEquity
DarioHealth initiated with a Buy at ThinkEquity
ENTA Enanta
$51.76 /

+0.38 (+0.74%)

02/09/21 RBC Capital
Enanta price target raised to $53 from $47 at RBC Capital
01/29/21 JPMorgan
Enanta upgraded to Neutral with $55 target at JPMorgan
01/29/21 JPMorgan
Enanta upgraded to Neutral from Underweight at JPMorgan
01/08/21 Piper Sandler
Enanta remains 'significantly undervalued,' says Piper Sandler
EQ Equillium
$7.87 /

-0.4 (-4.84%)

11/30/20 H.C. Wainwright
Equillium price target lowered to $12 from $22 at H.C. Wainwright
07/14/20 H.C. Wainwright
Equillium price target raised to $24 from $14 at H.C. Wainwright
07/10/20 Stifel
Equillium transferred with Buy rating, $10 target at Stifel
EXEL Exelixis
$22.69 /

+0.47 (+2.12%)

02/15/21 Piper Sandler
Exelixis price target raised to $36 from $33 at Piper Sandler
01/25/21 Piper Sandler
Piper says Exelixis could have 'blockbuster opportunity' with XL102
01/22/21 Piper Sandler
Exelixis combo approval came a month ahead of PDUFA, says Piper Sandler
01/20/21 William Blair
Exelixis selloff on competitive concerns an 'overreaction,' says William Blair
SDGR Schrodinger
$110.89 /

+2.09 (+1.92%)

01/25/21 BMO Capital
Schrodinger price target raised to $117 from $97 at BMO Capital
11/23/20 BofA
BofA upgrades Schrodinger to Buy after 'major' collaboration announcement
11/23/20 BofA
Schrodinger upgraded to Buy from Neutral at BofA
10/12/20 Jefferies
Schrodinger upgraded to Buy from Hold at Jefferies
VCYT Veracyte
$62.37 /

+0.88 (+1.43%)

SIEN Sientra
$8.05 /

-0.04 (-0.49%)

SDGR Schrodinger
$110.89 /

+2.09 (+1.92%)

MTCR Metracrine
$8.81 /

+0.21 (+2.44%)

LLY Eli Lilly
$204.64 /

+2.21 (+1.09%)

ITOS iTeos Therapeutics
$41.00 /

+1.05 (+2.63%)

IMRA Imara
$12.94 /

+0.62 (+5.03%)

HLIO Helios Technologies
$66.75 /

+1.46 (+2.24%)

EXEL Exelixis
$22.69 /

+0.47 (+2.12%)

EQ Equillium
$7.87 /

-0.4 (-4.84%)

ENTA Enanta
$51.76 /

+0.38 (+0.74%)

DRIO DarioHealth
$28.90 /

+0.15 (+0.52%)

CTSO CytoSorbents
$10.13 /

+0.04 (+0.40%)

CTLT Catalent
$115.09 /

+2.215 (+1.96%)

BBIO BridgeBio
$67.57 /

+1.67 (+2.53%)

AVXL Anavex
$12.38 /

+0.29 (+2.40%)

AUPH Aurinia Pharmaceuticals
$14.57 /

+0.21 (+1.46%)

ACRS Aclaris Therapeutics
$20.72 /

-0.3 (-1.43%)

  • 12
    Feb
  • 09
    Feb
  • 05
    Feb
  • 20
    Jan
  • 23
    Nov
  • 16
    Sep
  • 14
    Aug
  • 13
    Aug
  • 05
    Aug
  • 23
    Jul
  • 22
    Jul
  • 24
    Jul
  • 11
    Jun
  • 29
    May
  • 12
    Mar
LLY Eli Lilly
$204.64 /

+2.21 (+1.09%)

BBIO BridgeBio
$67.57 /

+1.67 (+2.53%)

AUPH Aurinia Pharmaceuticals
$14.57 /

+0.21 (+1.46%)

VINC Vincera Pharma
$20.21 /

+1.21 (+6.37%)

VCYT Veracyte
$62.37 /

+0.88 (+1.43%)

SIEN Sientra
$8.05 /

-0.04 (-0.49%)

SDGR Schrodinger
$110.89 /

+2.09 (+1.92%)

MTCR Metracrine
$8.81 /

+0.21 (+2.44%)

LLY Eli Lilly
$204.64 /

+2.21 (+1.09%)

IMRA Imara
$12.94 /

+0.62 (+5.03%)

EXEL Exelixis
$22.69 /

+0.47 (+2.12%)

EQ Equillium
$7.87 /

-0.4 (-4.84%)

ENTA Enanta
$51.76 /

+0.38 (+0.74%)

CTLT Catalent
$115.09 /

+2.215 (+1.96%)

BBIO BridgeBio
$67.57 /

+1.67 (+2.53%)

AVXL Anavex
$12.38 /

+0.29 (+2.40%)

AUPH Aurinia Pharmaceuticals
$14.57 /

+0.21 (+1.46%)

ACRS Aclaris Therapeutics
$20.72 /

-0.3 (-1.43%)

SDGR Schrodinger
$110.89 /

+2.09 (+1.92%)

LLY Eli Lilly
$204.64 /

+2.21 (+1.09%)

AUPH Aurinia Pharmaceuticals
$14.57 /

+0.21 (+1.46%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.